Patents by Inventor Luigi Maiuri

Luigi Maiuri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200206198
    Abstract: The present invention relates to a CFTR channel activator, or a pharmaceutical composition thereof, for use in the treatment and/or prevention of conditions of gluten sensitivity, such as a) celiac disease (CD) and/or a celiac-associated condition and/or gluten-related diseases, selected from potential celiac disease, refractory celiac disease, type 1 diabetes, autoimmune thyroiditis, or (b) non-celiac gluten sensitivity (NCGS) or irritable bowel disease.
    Type: Application
    Filed: July 25, 2018
    Publication date: July 2, 2020
    Inventor: Luigi Maiuri
  • Publication number: 20200179312
    Abstract: The present invention concerns a method of treatment of cystic fibrosis in a patient in need thereof, the method comprising administering an effective amount of a compound of formula I Wherein R1, X. Y and Z are as defined in the description.
    Type: Application
    Filed: November 22, 2019
    Publication date: June 11, 2020
    Applicant: I.E.R.F.C. EUROPEAN INSTITUTE FOR CYSTIC FIBROSIS RESEARCH
    Inventors: Luigi Maiuri, Valeria Villella, Fabio Borella, Giorgio Cozza, Andrea Venerando
  • Patent number: 9730922
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: August 15, 2017
    Assignee: I.E.R.F.C. Europ. Inst. for Cystic. Fibrosis Res.
    Inventors: Luigi Maiuri, Valeria Raia, Fabio Borella, Guido Kroemer
  • Publication number: 20150328203
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Application
    Filed: August 4, 2015
    Publication date: November 19, 2015
    Inventors: Luigi MAIURI, Valeria RAIA, Fabio BORELLA, Guido KROEMER
  • Patent number: 9132123
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: September 15, 2015
    Assignee: I.E.R.F.C. European Institute For Cystic Fibrosis Research
    Inventors: Luigi Maiuri, Valeria Raia, Fabio Borella, Guido Kroemer
  • Publication number: 20140227238
    Abstract: The present invention concerns peptides having protective effect towards inflammatory activity of a-gliadin 31-43 peptide in celiac disease and therefore can be used for preventive and therapeutic purpose by administration thereof to subjects at high risk to develop celiac disease and/or celiac subjects just before a gluten containing meal to be ingested.
    Type: Application
    Filed: September 18, 2012
    Publication date: August 14, 2014
    Applicants: Istituto Superiore Di Sanita, CRA-Sonsiglio per La Ricerca E LA
    Inventors: Marco Silano, Luigi Cattivelli, Pasquale De Vita, Luigi Maiuri, Donatella Bianca Maria Ficco